LUMO - Lumos Pharma, Inc.

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 29.05M
Enterprise value -28.51M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.09
Price/book (mrq)0.55
Enterprise value/revenue -13.56
Enterprise value/EBITDA 0.88

Trading information

Stock price history

Beta (5Y monthly) 0.65
52-week change 3-50.85%
S&P500 52-week change 31.77%
52-week high 39.5600
52-week low 32.9500
50-day moving average 33.3458
200-day moving average 35.3565

Share statistics

Avg vol (3-month) 313.08k
Avg vol (10-day) 322.22k
Shares outstanding 58.17M
Implied shares outstanding 6N/A
Float 84.67M
% held by insiders 138.43%
% held by institutions 130.03%
Shares short (14 May 2023) 4168.51k
Short ratio (14 May 2023) 412.58
Short % of float (14 May 2023) 42.91%
Short % of shares outstanding (14 May 2023) 42.06%
Shares short (prior month 13 Apr 2023) 4170.76k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 318 Mar 2020
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)-1,537.99%

Management effectiveness

Return on assets (ttm)-25.76%
Return on equity (ttm)-45.69%

Income statement

Revenue (ttm)2.1M
Revenue per share (ttm)0.25
Quarterly revenue growth (yoy)522.50%
Gross profit (ttm)1.52M
Net income avi to common (ttm)-30.69M
Diluted EPS (ttm)-3.8300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)57.98M
Total cash per share (mrq)7.1
Total debt (mrq)421k
Total debt/equity (mrq)0.80
Current ratio (mrq)12.61
Book value per share (mrq)6.42

Cash flow statement

Operating cash flow (ttm)-27.79M
Levered free cash flow (ttm)-17.34M